Phase II trial of daratumumab with DCEP in relapsed/refractory multiple myeloma patients with extramedullary disease

Abstract

Key points 1. This is one of the very few prospective trials focusing on refractory multiple myeloma with extramdedullary disease (EMD). 2. We successfully laid grounds for implementing immunochemotherapy in EMD treatment.

Keywords

• Multiple myeloma
• Relapse/refractory
• Extramedullary multiple myeloma
• Daratumumab
• DCEP